MiraKind Research Registry for PROSTOX

PROSTOX through the MiraKind Research Registry

You are eligible to obtain PROSTOX testing through the MiraKind Research Registry if you:

  • Have a localized prostate cancer diagnosis
  • Have not received radiation therapy to the prostate
  • Agree to participate in the MiraKind Research Registry, which entails responding to periodic questionnaires.
  • Are unable to have a physician order PROSTOX directly at this time or live outside of the US

Also, you must be considering one or more of these types of radiation therapy to the prostate:

  • SBRT, 5-7 sessions over 10 days
  • CFRT, 35-45 sessions over 8-10 weeks
  • MHFRT, 20-28 sessions over 5-7 weeks

$500* each
or $900* for both tests

Start Now

*This discounted cost for PROSTOX is only available through the MiraKind Research Registry. 20% of your purchase supports MiraKind.

Questions? Read FAQ or email prostox@miradx.com

Frequently asked questions about PROSTOX testing through the MiraKind Research Registry

Accessing PROSTOX
How do I know if I am eligible to get PROSTOX through the MiraKind Research Registry?
Do I need a doctor to order PROSTOX through the MiraKind Research Registry?
What if I need financial assistance?
Taking the test
How do I collect my sample?
How do I return my kit?
What is the turnaround time for results?
How will I receive my PROSTOX results?
Participating in our research registry
What is MiraKind's "Research Registry"?
What are the benefits of participating in a MiraKind Research Registry?
What will happen to my information if I participate in a MiraKind Research Registry?

Disclosure: Any discussion of medical management options is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

  1. Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
  2. Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
  3. Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.
  4. Kishan AU, Marco N, Ma TM, Steinberg ML, Sachdeva A, Cao M, Ballas LK, Rietdorf E, Telesca D, Weidhaas JB. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clin Transl Radiat Oncol. 2023 Feb 8;39:100594. doi: 10.1016/j.ctro.2023.100594. PMID: 36880064; PMCID: PMC9984404.
  5. Kishan AU, et al. Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer. Clin Cancer Res 15 June 2025; 31 (12): 2530–2538.

about MiraKind

MiraKind is a 501(c)(3) non-profit organization in Los Angeles, CA.
All donations are tax-deductible.
EIN 46-4451492.

education

testing information

research

our research

studies

hormones, the KRAS-variant and breast cancer risk study

publications

get involved

subscribe to our newsletter

Subscribe Now

socials

Disclaimer: Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.